Methods Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control.
Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay …

Volume_28 Number_2 April 2022 regulation of serum TNF-α levels in patients with liver
cirrhosis. In fact, a variety of basic and clinical studies have implicated that gut dysbiosis …

Objective Sarcopenia is one of the most significant contributors to morbidity in patients with
chronic liver disease. Serum myokines are potential biomarkers for detecting early …

Background and aims The pathophysiology of sarcopenia in cirrhosis is poorly understood.
We aimed to evaluate the histological alterations in the muscle tissue of patients with …

Aim This study aimed to elucidate a surrogate marker of sarcopenia in patients with liver
cirrhosis (LC). Methods A total of 424 patients were assessed for handgrip strength (HGS) …

Background Sarcopenia is associated with a poor prognosis in patients with liver cirrhosis.
However, it is not known whether the rate of skeletal muscle depletion is also associated …

Nonalcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver
disease. NAFLD encompasses a group of conditions where there is an accumulation of …

Background Diagnostic criteria for sarcopenia have not been established in Chinese. This
study established criteria based on the L3‐skeletal muscle index (L3‐SMI) and assessed its …

Sarcopenia is a disease characterized by decreased muscle mass and strength, affecting 20–
70% of patients with cirrhosis, and is associated with poor prognosis, complications, and …

The gut‑liver‑muscle axis is associated with the development of sarcopenia in liver cirrhosis.
The present study aimed to illustrate the combined effects of rifaximin and L‑carnitine on …